DEPOSITION OF PG-M/VERSICAN IS A MAJOR CAUSE OF HUMAN CORONARY RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
- 1 November 1996
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 180 (3), 311-316
- https://doi.org/10.1002/(sici)1096-9896(199611)180:3<311::aid-path657>3.0.co;2-b
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Animal models of restenosisTrends in Cardiovascular Medicine, 1994
- Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy.Circulation Research, 1993
- Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.Journal of Clinical Investigation, 1993
- Pharmacologic prevention of restenosis after coronary angioplastyCoronary Artery Disease, 1993
- Directional atherectomy for treatment of restenosis within coronary stents: Clinical, angiographic and histologic resultsJournal of the American College of Cardiology, 1992
- Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.Circulation, 1992
- Clinical trials of restenosis after coronary angioplasty.Circulation, 1991
- ProteoglycansPublished by Springer Nature ,1991
- Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplastyAmerican Heart Journal, 1989
- Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1986